Combining Pembrolizumab with Microwave Ablation for Advanced Lung Cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the safety and efficacy of combining Pembrolizumab, an immunotherapy drug, with microwave ablation in patients with advanced non-small cell lung cancer (NSCLC) who have not responded to first-line treatments. The study aims to stimulate an immune response through local thermal ablation while administering Pembrolizumab to enhance anti-tumor effects. It is a prospective, randomized, single clinical study focusing on patients with stage IIIB-IV NSCLC. The trial will assess the outcomes of this combined approach in improving patient survival and quality of life.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Pathologically diagnosed IIIB or IV non-small cell lung cancer.
2. Previously accepted first-line standard treatment failure or recurrence
3. At least one measurable lesion.
4. The patient has not received any other anti-cancer treatment within four weeks.
5. Any gender, age ≥18 years
6. ECOG PS : 0-2 points
7. Expected survival ≥ 6 months
8. The level of organ function meets the following criteria.

(1) subject to the standard blood test: ANC ≥ 1.5×109 / L, PLT ≥ 50×109 / L, Hb ≥ 90g/L.

(2) biochemical tests must meet the following criteria: TBIL\<1.5×ULN, ALT, AST \<2.5×ULN ( if liver metastasis ALT, AST can be \<5×ULN), BUN, and Cr ≤ 1×ULN).

9\. Female patients in child bearing period must have evidence of negative pregnancy test, and agree to take effective contraceptive measures until 6months after therapy.

10\. Subjects volunteered to join the study, signed informed consent, good compliance, with follow-up.

Exclusion Criteria:

1. Patients with two or more kinds of tumors.
2. Patients with active viral or bacterial infection, and have failed to be controlled by anti-infective treatment.
3. Patients with seropositive response of Human immunodeficiency virus (HIV) and syphilis, or fail to control the hepatitis B virus or hepatitis C virus infection.
4. Patients with active rheumatic diseases, organ transplantation and other diseases affecting the immune system seriously.
5. Patients with severe heart and lung dysfunction.
6. Patients with severe chronic diseases of kidney, liver and other important organs.
7. Patients with any other serious illness that the investigators consider it will may affect the patient's treatments, follow-up or assessment, including any uncontrolled clinically significant neurological or psychiatric disorders, immunoregulatory diseases, metabolic diseases, infectious diseases and so on.
8. Patients who take part in clinical trials of other drugs or biological therapy at present or within 30 days before enrollment.
9. Patients who need long-term use of immunosuppressive drugs or patients who are undergoing treatment of autoimmune diseases.
10. Patients who need long-term use of glucocorticoid.
11. Women patients in gestation period or suckling period.

Where it's running

• zhang Zhenfeng
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Principal investigator: zhang zhenfeng, MD,PHD — Second Affiliated Hospital of Guangzhou Medical University
• Study coordinator: zhang zhenfeng, MD,PHD
• Email: zhangzhf@gzhmu.edu.cn
• Phone: 02034153532

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• First-line treatment with pembrolizumab, pemetrexed, and platinum with or without zoldonrasib for metastatic non-squamous NSCLC

  This trial tests whether adding zoldonrasib to standard pembrolizumab and platinum chemotherapy helps people with untreated metastatic non-squamous NSCLC that has a RAS G12D mutation.

  Recruiting at 4 sites Phase 3 Revolution Medicines, Inc. · Anchorage, Alaska and 3 other locations · NCT07777822

• ABBV-1480 plus chemotherapy vs pembrolizumab plus chemotherapy as first-line treatment for locally advanced or metastatic non-small cell lung cancer

  This study tests whether ABBV-1480 with platinum-based chemotherapy can work better than pembrolizumab with chemotherapy for adults with certain stages of non-small cell lung cancer.

  Recruiting at 2 sites Phase 3 AbbVie · Fort Wayne, Indiana and 1 other locations · NCT07756645

• Adjuvant intismeran (V940) with or without pembrolizumab plus berahyaluronidase alfa for high‑risk Stage I non‑small cell lung cancer after surgery

  This trial will try intismeran (V940) alone or together with subcutaneous pembrolizumab plus berahyaluronidase alfa to help prevent recurrence in people with completely removed high‑risk Stage I non‑small cell lung cancer.

  Recruiting at 126 sites Phase 3 Merck Sharp & Dohme LLC · Sacramento, California and 125 other locations · NCT07513376

• Adjuvant calderasib with subcutaneous pembrolizumab plus berahyaluronidase alfa for completely resected KRAS G12C stage IIA–IIIB (N2) NSCLC

  This trial tests whether adding the oral KRAS G12C inhibitor calderasib to subcutaneous pembrolizumab plus berahyaluronidase alfa helps prevent recurrence in people with completely resected stage IIA–IIIB (N2) KRAS G12C non‑small cell lung cancer.

  Recruiting at 122 sites Phase 3 Merck Sharp & Dohme LLC · Ciudad Autónoma de Buenos Aires, Buenos Aires and 121 other locations · NCT07431827

• PF-08634404 plus chemotherapy versus pembrolizumab-based chemotherapy for advanced non-small cell lung cancer

  This will test whether PF-08634404 combined with chemotherapy works better than pembrolizumab plus chemotherapy for adults with locally advanced or metastatic non-small cell lung cancer who have not received prior treatment for their advanced disease.

  Recruiting at 464 sites Phase 3 Pfizer · Bullhead City, Arizona and 483 other locations · NCT07222566

• Calderasib plus subcutaneous pembrolizumab for KRAS G12C non-small cell lung cancer

  This trial will test whether adding the KRAS G12C drug calderasib to subcutaneous pembrolizumab helps people with advanced nonsquamous non‑small cell lung cancer live longer without the cancer growing compared with pembrolizumab plus chemotherapy.

  Recruiting at 221 sites Phase 3 Merck Sharp & Dohme LLC · Birmingham, Alabama and 224 other locations · NCT07190248

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.